Monday, April 2, 2012
The drug ibrutinib (PCI-32765), in development by Pharmacyclics Inc., of Sunnyvale, Calif., and Janssen Research and Development LLC, a unit of Johnson & Johnson, showed significant anti-cancer responses and modest side effects in a pilot trial in the activated B-cell form of diffuse large B-cell lymphoma. Subjects received 560 mg daily until progression of the disease. There were multiple responses and some complete remissions.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.